bioRxiv / medRxiv
open access
CC BY-NC-ND 4.0
In Vitro Ketamine Attenuates Immune Sensitization in Major Depressive Disorder in a Concentration-Dependent Manner
BackgroundMajor depressive disorder (MDD) is a severe mental illness associated with severe clinical consequences and substantial societal burden. Its characterized by immune-inflammatory dysregulation and immune sensitization. ObjectiveTo determine whether in vitro ketamine attenuates phytohemaggl
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- The dynamics of AMPA receptors underlies the efficacy of ketamine in treatment resistant patients with depression.#285304
- Intramuscular Ketamine Versus Aripiprazole and Escitalopram in the Treatment of Resistant Depression#845190
- IL-1β pathway-dependent regulation of glutamate receptor activity by gut microbiota in bipolar depression.#457738
- Distinct therapeutic profiles of ketamine in treatment-resistant depression: an exploratory analysis.#218818
- Psilocybin rapidly, but not immediately, reverses reward learning deficits in a durable manner in an inflammatory rat model of depressive symptoms#273179
Record · ID 1149604
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive